VRDN
Viridian Therapeutics, Inc.\DE
Key Financials
Operating Income
$-363395000
↓ 21.5%
Net Income
$-342601000
↓ 26.9%
Revenue
$4.0M
↑ 235.8%
EPS (Diluted)
$-5.31
↓ 31.1%
Shareholders' Equity
$722.2M
↑ 7.5%
Total Assets
$899.4M
↑ 21.1%
Total Liabilities
$177.3M
↑ 150.5%
Long-term Debt
$20.6M
↑ 1.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/7/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VRDN |
| Company Name | Viridian Therapeutics, Inc.\DE |
| CIK | 1590750 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617.272.4600 |